Ali Behbahani MD

Ali Behbahani MD General Information

Biography

Dr. Ali Behbahani serves as Partner and Co-Head of Healthcare at New Enterprise Associates. He served as a Board Member at Ivantis, Korro, Tune Therapeutics, and SpyGlass Pharma. He served as a Board Member at Genocea Biosciences & ExploraMed. He served as a Board Member at Prospect Medical and Solace Therapeutics, He serves as a Board Member of Black Diamond Therapeutics, 858 Therapeutics, Stablix Therapeutics, Monte Rosa Therapeutics, and serves as Board Member, Member of Audit Committee & Member of Corporate Governance & Nominating Committee at Oyster Point Pharmaceuticals. He serves as Non-Executive Director at Adaptimmune Therapeutics. He formerly served as a Partner. He has seen the healthcare and innovation ecosystems from nearly every angle, previously holding positions as a Venture Associate at Morgan Stanley Venture Partners, as a consultant in business development at The Medicines Company, and as a Healthcare Investment Banking Analyst at Lehman Brothers. He concurrently earned an MD from The University of Pennsylvania School of Medicine and an MBA from The University of Pennsylvania Wharton School. He serves on the boards of directors of the following companies: Adaptimmune, Arcellx, Cardionomic, CVRx, Genocea, Ivantis, Minerva Surgical, Nevro, and Nkarta. He serves as a director at CRISPR Therapeutics. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and Duke University. He concurrently earned his MD degree from The University of Pennsylvania School of Medicine and his MBA degree from The University of Pennsylvania Wharton School, where he graduated with Honors and was a Palmer Scholar. He graduated summa cum laude and received his bachelor's degrees with distinction in Biomedical Engineering, Electrical Engineering, and Chemistry from Duke University.